Group I (n = 70) were treated by ATDs for more than 6 months and stopped it 5 days; group II (n = 70) were treated by ATDs for more than 6 months but stopped it only for two days or less, and group III (n = 60) had never been treated with ATD before RAI treatment (control group). Results:
INTRODUCTION:
Graves' disease (GD) is autoimmune disorders in which thyroid-stimulating hormone receptor antibodies can cause the thyroid gland synthesize large amounts of thyroid hormones. It is the most common cause of hyperthyroidism Pre-treatment with ATDs is indicated in older patients, in those with severe hyperthyroidism and cardiovascular complications.
In such patients, it is common practice to achieve euthyroid state to reduce the risk of worsening of thyrotoxicosis due to radiation induced leakage of stored thyroid hormone, which can occur soon after RAI therapy
. . The reported recurrence rates after RAI treatment range from 10 to 40 percent of patients, with more severe cases of hyperthyroidism associated with higher rates of failure (10, 11) . Absolute contraindications to RAI are few and include pregnancy, lactation, and inability to comply with radiation safety guidelines after treatment (12, 13) .
PATIENTS and METHODS:
The with ATDs for 6 months or more, all patients were followed for 6 months after RAI-131 therapy.
The patients were classified into three groups: Group I (n = 70) were treated by ATDs for more than 6 months and stopped it 5 days; group II (n = 70) were treated by
ATDs for more than 6 months but stopped it only for two days or less, and group III (n = 60) had never been treated with ATD before RAI treatment (control group). Hypothyroidism was defined as low thyroid hormone and increased TSHs.
Cured rates were observed 3 and 6 months after radioactive iodine. Fifty (25%) patients received another dose of RAI-131 post 6 months due to persistent symptoms of thyrotoxicosis and high FT3, FT4, and low TSH levels). 
RESULTS:
This study included 200 patients, that were clinically & radio-laboratory diagnosed as GD. They were divided into three groups according to either they were received pre-RAI-131 medical treatment or not, and when they stopped it before RAI-131 treatment. Table 2) .
There was a statistical significant difference in cure rate between the group I and the group II (P < 0.001), group II and group III (P < 0.001), but no statistical significant difference between group I and group III (P = 0.453) three months after radioactive iodine therapy.
There was a statistical significant difference in the cure rate between group I and the group II (P =0.002), group II and group III (P < 0.001), but no statistical significant difference between group I and group III (P =0.060) at 6 months after radioactive iodine therapy. However, there was a statistical significant difference between the three groups 3 months (P < 0.001), and 6 months (P < 0.001), after radioactive iodine therapy (Table 3) . (Fig 1) . Cure rates 3 and 6 months after radioactive iodine therapy in all groups. (Table 3) . Comparison of cure rates 3 and 6 months after radioactive iodine therapy between the studied groups. .Carbimazole (CMZ),
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Another meta-analysis suggests that all anti thyroid medication should be withheld for at least a week prior to therapy to improve the outcome (7, 19) .
The effect of oral ATDs on radioactive iodine therapy had been studied for a long can be improved by discontinuation of these drugs more than 3 days (20, 21) .
Some studies suggested that the ATDs may have a protective effect, which leads to lowering the effective half-life and uptake of radioactive iodine in the thyroid gland.
Thus, the target organ (thyroid) dose will decrease, resulting in a decrease of the effectiveness of radioactive iodine therapy.
Moka et al. stated that discontinuation of
ATDs before radioactive iodine is needed. .
In this study, 12 mCi of radioactive iodine based on our empirical experience for fixed dose was used, as all patients in this Study had mildly enlarged gland as detected by thyroid scan and thyroid ultrasound.
There was a statistical significant difference in the cure rate between the group I and the group II (P < 0.001), group II and group III (P < 0.001), but no statistical significant difference between group I and group III (P = 0.453) three months after radioactive iodine therapy.
There was also a statistical significant difference in the cure rate between group I and the group II (P =0.002), group II and group III (P < 0.001), but no statistical significant difference between group I and group III (P =0.060) at 6 months after radioactive iodine therapy.
However, there was a statistical significant difference between the three groups 3 months (P < 0.001), and 6 months (P < 0.001), after radioactive iodine therapy. .
CONCLUSIONS:
The administration of oral ATDs more than 6 months without withdrawal for 5 days decreased response of radioactive iodine therapy in the 3 and 6 months' follow-up in GD patients. Discontinuation of ATDs for 5 days before RAI treatment is recommended.
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